In prostate cancer, we're using combinations by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, MD Anderson Cancer Center.
In prostate cancer, combination therapies are being used to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, Cancer Medicine, MD Anderson Cancer Center.
Transcript (slightly modified)
Prostate cancer has had lower response rates to single-agent immune checkpoint inhibitors than other cancers. How are you working towards understanding who will have the best response to these inhibitors?
It’s been a real struggle to get the response we see in malignancies such as melanoma, kidney, and bladder. What we’re starting to understand is that the prostate cancer tumor microenvironment is just really an immunosuppressive 1, and so the strategies we’re using now is using combinations, and rational combinations, by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy.
So, for example we’ve completed a trial where we were doing ipilimumab plus anti- PD-1, and the reason for that was after giving 2 doses of ipilimumab, we found that the tumor microenvironment upregulates both PD-1 and PD-L1, so by doing the combination, we should see better responses, and so far it looks like the early signals show that. We’re getting better response, but not as well as we see in melanoma.
What we’re going to have to do is find out who are these patients that actually respond so that we can enrich that population and then also better understand why the other patients are not responding.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More